Gilead Pays $200-Million Milestone for Liver-Disease Drug
By
Gilead Sciences has made a $200-million milestone payment to Nimbus Therapeutics, a biotechnology company headquartered in Cambridge, Massachusetts, related to Gilead’s allosteric acetyl-CoA carboxylase (ACC) inhibitor program with drug candidate…
Medivir to Acquire Oncology Programs in $238-Million Deal
By
Medivir, a Stockholm, Sweden-based pharmaceutical company, has agreed to acquire two clinical-stage oncology programs from Tetralogic Pharmaceuticals, a Malvern, Pennsylvania-based biopharmaceutical company in a deal valued up to $238 million. The…
Celldex Acquires Immuno-Oncology Portfolio in $235-Million Deal
By
Celldex Therapeutics, a Hampton, New Jersey-based pharmaceutical company, has agreed to acquire Kolltan Pharmaceuticals, a privately held clinical-stage company based in New Haven, Connecticut focused primarily in oncology, to boost…